Report
EUR 88.49
For Business Accounts Only
Despite the small deal size, what interests us is that Orbimed, a specialized healthcare investor, committed USD 30 million in the deal. In this note, we will quickly look at the company’s products and pipelines.
We highlight interesting findings in its operations and financials and touched upon its valuation briefly. With an undemanding valuation and market leadership in the cardiovascular device segment with decent growth, we would participate in the deal.
Shanghai Kindly Medical Instruments (康德莱医疗) IPO - Cardiovascular device leader backed by strong cornerstone investor
Shanghai Kindly Medical Instrument is a leading domestic player in the cardiovascular interventional device market, particularly the Percutaneous Coronary Intervention (PCI) segment. Yesterday, the company launched its book building to raise up to USD 106 million.Despite the small deal size, what interests us is that Orbimed, a specialized healthcare investor, committed USD 30 million in the deal. In this note, we will quickly look at the company’s products and pipelines.
We highlight interesting findings in its operations and financials and touched upon its valuation briefly. With an undemanding valuation and market leadership in the cardiovascular device segment with decent growth, we would participate in the deal.
Provider
Aequitas Research
Aequitas Research is a leading ECM research firm with a focus on IPOs and placements/follow-on offerings across the Asia Pacific with deal size of over USD100m.
Since 2015, we have covered 400+ IPOs and 450+ placements with a hit rate of 73% and 65%, respectively. We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic analysis.
Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis. We also provide a more quant driven analysis on placement/follow-on offerings.
Markets that we cover include:
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.
Ke Yan
Other Reports from Aequitas Research
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.